Endocrine therapy for prostate cancer.
Prostate cancer is the most frequent cancer in men. A discovery of major importance in the endocrinology of prostate cancer is that the testes contribute only 60% of total androgens in adult men; the remaining 40% are synthesized in peripheral tissues, including the normal and cancerous prostate, from inactive androgen precursors of adrenal origin. Using a combination therapy that includes a pure blocker of the androgen receptor or antiandrogen and castration (medical with luteinizing hormone-releasing hormone agonist or surgical by orchiectomy), the duration of response and survival have been demonstrated to be prolonged for the first time in advanced prostate cancer.
Labrie
F
F
Department of Molecular Endocrinology, CHUL Research Center, Quebec, Canada.
D000726:Androgen Antagonists / Q000627:therapeutic use*; D059002:Androgen Receptor Antagonists; D000728:Androgens / Q000096:biosynthesis / Q000235:genetics; D003131:Combined Modality Therapy; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000726:Androgen Antagonists; D059002:Androgen Receptor Antagonists; D000728:Androgens; D007987:Gonadotropin-Releasing Hormone